Chemical castration induced by adjuvant cyciophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1341-1347

  Saarto, T ^a   Blomqvist, C ^a   Valimaki M ^a   Makela P ^a   Sarna, S ^a   Elomaa, I ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN RECEPTOR; FLUOROURACIL; FOLLITROPIN; LUTEINIZING HORMONE; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AMENORRHEA; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER ADJUVANT THERAPY; CASTRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OVARY INSUFFICIENCY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0031003458     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1341     Document Type: Article

References (37)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 72-85, 1992
2. Padmanabhan N, Wang DY, Moore JW, et al: Ovarian function and adjuvant chemotherapy for early breast cancer. Eur J Cancer Clin Oncol 23:745-748, 1987
3. Richards MA, O'Reilly SM, Howell A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol 8:2032-2039, 1990
4. Bianco AR, Del Mastro L, Gallo C, et al: Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 63:799-803, 1991
5. Richelson LS, Wahner HW, Melton III LJ, et al: Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311:1273-1275, 1984
6. Genant HK, Cann CE, Ettinger B, et al: Quantitative computed tomography of vertebral spongiosa: A sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699-705, 1982
7. Pouilles JM, Tremollieres F, Bonneu M, et al: Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 9:311-315, 1994
8. Lindsay R, Hart DM, Aitken JM, et al: Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1:1038-1041, 1976
9. Lindsay R: Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 95:37S-39S, 1993
10. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al: Estrogen replacement therapy I: A 10-year prospective study in the relationship to osteoporosis. Obstct Gynecol 53:277-281, 1979
11. Christiansen C, Christensen MS, McNair P, et al: Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273-279, 1980
12. Recker RR, Saville PD, Heaney RP: Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. Ann Intern Med 87:649-655, 1977
13. Stevenson JC, Cust MP, Gangar KF, et al: Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopasul women. Lancet 336:265-269, 1990
14. Ettinger B, Genant HK, Cann CE: Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 106:40-45, 1987
15. Ettinger B, Genant HK, Steiger P, et al: Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 166:479-488, 1992
16. Genant HK, Baylink DJ, Gallagher JC, et al: Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol 76:579-584, 1990
17. Bruning PF, Pit MJ, de Jong-Bakker M, et al: Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308-310, 1990
18. Kreuser et al: Long term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 3:105-110, 1992 (suppl 4)
19. Reginster JY, Lecart MP, Deroisy R, et al: Prevention of postmenopausal bone loss by tiludronate. Lancet 2:1469-1471, 1989
20. Storm T, Thamsborg G, Steiniche T, et al: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271, 1990
21. Watts NB, Harris ST, Genant HK, et al: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79, 1990
22. Reid IR, Wattie DJ, Evans MC, et al: Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-1599, 1994
23. Giannini S, D'Angelo A, Malvasi L, et al: Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14:137-141, 1993
24. Harris ST, Watts NB, Jackson RD, et al: Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567, 1993
25. Chesnut III CH: Treatment of postmenopausal osteoporosis. Compr Ther 10:41-47, 1984
26. Filipponi P, Pedetti M, Fedeli L, et al: Cyclic clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10:697-703, 1995
27. Liberman UR, Weiss SR, Bröll J, et al: Effect of oral alendronate on bone minenral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443, 1995
28. Elomaa I, Blomqvist C, Grohn P, et al: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1:146-149, 1983
29. Martoni A, Guaraldi M, Camera P, et al: Controlled clinical study on the use of dichloromethylene diphosphonate in patients with metastasizing to skeleton. Oncology 48:97-101, 1991
30. Paterson AH, Powles TJ, Kanis JA, et al: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993
31. Van Holten Verzantvoort ATM, Kroon HM, Bijvoet OL, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
32. Riggs BL, Wahner HW, Melton III LJ, et al: Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 77:1487-1491, 1986
33. Harris S, Dawson HB: Rates of change in bone mineral density of the spine, heel, femoral neck and radius in healthy postmenopausal women. Bone Miner 17:87-95, 1992
34. Pouilles JM, Tremollieres F, Ribot C: The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 52:340-343, 1993
35. Pouilles JM, Tremollieres F, Ribot C: Effect of menopause on femoral and vertebral bene loss. J Bone Miner Res 10:1531-1536, 1995
36. Yasuda M, Kurabayashi T, Yamamoto Y, et al: Effect of hormone replacement therapy on bone and lipid metabolism in women oophorectomized for the treatment of gynecologic malignancies. Int J Gynecol Obstet 47:151-156, 1994
37. McCloskey EV, Beneton MNC, O'Rourke N, et al: The effect of phosphate and intermittent clodronate in postmenopausal osteoporosis, in Christiansen C, Overgard K (eds): Osteoporosis 90. Copenhagen, Denmark, 1990, pp 1401-1402